Azitra (AZTR) Change in Receivables (2022 - 2026)
Azitra (AZTR) posted Change in Receivables of $4196.0 for Q1 2026, up 360.09% on a QoQ basis from $912.0 in Q4 2025, and up 1900.86% year-over-year from $209.71 in Q1 2025.
Azitra (AZTR) Change in Receivables (2022 - 2026) Analysis & Trends
Azitra's Change in Receivables history runs 5 years deep, the most recent figure standing at $4196.0 for Q1 2026.
- Quarterly Change in Receivables rose 1900.86% year-over-year to $4196.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5108.0 (up 375.07% YoY) and the FY2025 annual result came in at $679.0, up 100.69% from the prior year.
- Change in Receivables was $4196.0 for Q1 2026 at Azitra, up from $912.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $347731.0 in Q2 2023 and bottomed at -$445120.0 in Q3 2023.
- A 5-year average of -$1612.2 and a median of $233.0 in 2024 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2023 — Change in Receivables sank 846.49% — and 2026, when it jumped 1900.86%.
- Azitra's Change in Receivables stood at $97125.0 in 2022, then climbed by 1.16% to $98255.0 in 2023, then sank by 99.76% to $233.0 in 2024, then surged by 291.42% to $912.0 in 2025, then surged by 360.09% to $4196.0 in 2026.
- Business Quant data shows AZTR's Change in Receivables at $4196.0 in Q1 2026, $912.0 in Q4 2025, and -$233.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - | - |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn | 75.30 Mn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn | -39.80 Mn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn | -1.20 Mn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn | 110.42 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - | - |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - | 4,196.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,196.00 |
| Mar 31, 2026 | 4,196.00 |
| Dec 31, 2025 | 912.00 |
| Dec 31, 2025 | 912.00 |
| Mar 31, 2025 | -233.00 |
| Mar 31, 2025 | -233.00 |
| Dec 31, 2024 | 233.00 |
| Dec 31, 2024 | 233.00 |
| Sep 30, 2024 | -1,125.00 |
| Sep 30, 2024 | -1,125.00 |
| Jun 30, 2024 | -732.00 |
| Jun 30, 2024 | -732.00 |
| Mar 31, 2024 | -96,398.00 |
| Mar 31, 2024 | -96,398.00 |
| Dec 31, 2023 | 98,255.00 |
| Dec 31, 2023 | 98,255.00 |
| Sep 30, 2023 | -445,120.00 |
| Sep 30, 2023 | -445,120.00 |
| Jun 30, 2023 | 347,731.00 |
| Jun 30, 2023 | 347,731.00 |